TaiMed Biologics Cash Flow-to-Debt Ratio
TaiMed Biologics cash flow-to-debt ratio. TaiMed Biologics (4147) has a Cash Flow-to-Debt Ratio of 0.07x as of June 2026, meaning its operating cash flow of NT$58.88 Million could theoretically repay 0% of its total liabilities (NT$824.49 Million) in one year. Check total reinvestment intensity of TaiMed Biologics to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of TaiMed Biologics (2015–2025)
Cash flow-to-debt ratio of TaiMed Biologics from 2015 to 2025. Historical debt coverage capacity for TaiMed Biologics across 11 annual periods. Check TaiMed Biologics (4147) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
TaiMed Biologics Cash Flow-to-Debt Ratio by Year (2015–2025)
TaiMed Biologics cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for TaiMed Biologics. For the full cash flow conversion analysis, see 4147 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | NT$191.14 Million | NT$953.05 Million | ▲ +151.6% |
| 2024 | -0.39x | NT$-379.55 Million | NT$976.34 Million | ▼ -1916.3% |
| 2023 | -0.02x | NT$-25.60 Million | NT$1.33 Billion | ▲ +95.6% |
| 2022 | -0.44x | NT$-605.21 Million | NT$1.39 Billion | ▼ -244.9% |
| 2021 | -0.13x | NT$-211.28 Million | NT$1.67 Billion | ▼ -11.6% |
| 2020 | -0.11x | NT$-201.94 Million | NT$1.78 Billion | ▲ +80.2% |
| 2019 | -0.57x | NT$-655.31 Million | NT$1.14 Billion | ▲ +22.2% |
| 2018 | -0.74x | NT$-522.86 Million | NT$710.55 Million | ▲ +70.0% |
| 2017 | -2.45x | NT$-516.48 Million | NT$210.71 Million | ▼ -25.2% |
| 2016 | -1.96x | NT$-172.29 Million | NT$87.99 Million | ▲ +88.3% |
| 2015 | -16.76x | NT$-446.26 Million | NT$26.63 Million | — |